While the composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack
Apr 8, 2024
0
0
For young people, empagliflozin is associated with improvement in glycated hemoglobin (HbA1c), according to a study published in the March issue of The Lancet Diabetes & Endocrinology.
Mar 21, 2023
0
0
Type 2 diabetes is a chronic disease in which the body does not produce enough of the hormone insulin, which regulates blood sugar, while cells in the muscle, fat and digestive system simultaneously become less sensitive ...
Feb 23, 2023
0
46
For patients hospitalized for acute heart failure, treatment with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin produces clinical benefit, according to a study published online April 4 in Circulation ...
Apr 13, 2022
0
9
Adults treated with empagliflozin during hospitalization for acute heart failure experienced a clinical benefit such as increased survival, lower risk of heart failure hospital readmission and an overall improvement in their ...
Nov 15, 2021
0
3
Empagliflozin reduces the risk of a composite of cardiovascular death or hospitalization for heart failure in patients with heart failure and a preserved ejection fraction (HFpEF) with or without diabetes. That's the finding ...
Aug 27, 2021
0
176
A pooled analysis of two randomized trials has demonstrated the beneficial effects of empagliflozin in patients with heart failure with a reduced and preserved ejection fraction. The late breaking study is presented in a ...
Aug 27, 2021
0
2
Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai.
Nov 13, 2020
0
14
Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction. That's the finding of the EMPEROR-Reduced trial presented in a Hot ...
Aug 31, 2020
0
6
Researchers at the Icahn School of Medicine at Mount Sinai have demonstrated that the recently developed antidiabetic drug empagliflozin can treat and reverse the progression of heart failure in non-diabetic animal models. ...
Apr 18, 2019
0
9
